Last reviewed · How we verify
NCT05075330
SMART Trial: Community Stigma Reduction
NA trial testing Opioid Use Disorder Stigma Reduction in Opioid-use Disorder in 199 participants. Completed in 19 August 2021.
19 August 2021
Quick facts
| Lead sponsor | Karen Derefinko, PhD |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 199 |
| Start date | 16 June 2021 |
| Primary completion | 19 August 2021 |
| Estimated completion | 19 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Opioid Use Disorder Stigma Reduction
Conditions studied
- Opioid-use Disorder — all drugs for Opioid-use Disorder →
- Stigma, Social — all drugs for Stigma, Social →
Sponsor
Karen Derefinko, PhD
Who can join
18 and older, any sex, with Opioid-use Disorder or Stigma, Social. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this project is to engage community members from two low-income African American communities (N=200) in a survey study that assesses stigma toward those with Opioid Use Disorder (OUD). Those from the intervention community will be subject to a stigma reduction campaign via billboards. Those from the control community will not. Stigma will be re-assessed following the period of the campaign.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05075330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid-use Disorder
Currently open trials in the same condition.
- NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk · NA · active not recruiting
- NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder · Phase 2, PHASE3 · recruiting
- NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment · NA · recruiting
- NCT05033028 — Smartphones for Opiate Addiction Recovery · Phase 3 · recruiting
- NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr · NA · recruiting
Other Karen Derefinko, PhD trials
Trials by the same sponsor.
- NCT04080180 — SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence · NA · completed
- NCT04464421 — SMART Effectiveness Trial · NA · completed
- NCT04225468 — Safe Options for ACL Recovery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05075330 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karen Derefinko, PhD
- Last refreshed: 18 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05075330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing